Skip to main content
Top
Published in: Journal of Medical Case Reports 1/2014

Open Access 01-12-2014 | Case report

Atypical presentation of carcinoid tumor with unresolved right shoulder pain: a case report

Authors: Nay Thi Tun, Rajen Oza

Published in: Journal of Medical Case Reports | Issue 1/2014

Login to get access

Abstract

Introduction

Carcinoid tumors are variants of neuroendocrine tumors that typically arise from the gastrointestinal tract and the bronchus, but they can involve any organ. Unresolved right shoulder pain manifesting as the first clinical presentation of carcinoid tumor with unknown primary origin is a rare clinical entity. To the best of our knowledge, herein we present the first case report describing metastasis to the right shoulder joint in a patient who presented with bone pain as the first clinical manifestation of metastatic carcinoid tumor of unknown primary origin. Metastasis to the right scapula as the first presentation of an underlying carcinoid tumor in the primary bronchus has been reported previously.

Case presentation

A 72-year-old Caucasian woman presented with pain in her right shoulder after a fall. She delayed seeking medical attention for 4 weeks for personal reasons. Her physical examination revealed no erythema or swelling of the right shoulder. However, tenderness was noted on the right subacromial bursa and the right acromioclavicular joint. Her drop arm test was positive. An X-ray of the right upper extremity showed no fracture. She did not respond to methylprednisolone injections or physical therapy. Because of the unresolved right shoulder pain with disturbance of her daily activities, magnetic resonance imaging of the right shoulder was ordered, which revealed permeative destruction of the right scapula. Because the permeative destruction of the bone could have been an osteolytic malignant feature, positron emission tomography–computed tomography was performed, which produced a scan showing osseous metastasis to the right scapula, multiple liver metastases and a 1.7cm right-lower-lobe pulmonary nodule. Her serotonin and chromogranin A levels were significantly elevated. The patient was treated with palliative cisplatin and etoposide chemotherapy followed by locoregional treatments for metastatic carcinoid tumor. She had mild improvement in her right shoulder pain, as well as better range of motion and improved quality of life, before she died less than 2 years after her diagnosis.

Conclusion

Our present case report emphasizes the protean manifestations of carcinoid tumors with the importance of early diagnosis of bone metastases from these tumors, because early diagnosis plays a major role in choosing the therapeutic regimen and prognosticating the course of the disease. The treatment goals for high-grade, poorly differentiated carcinoid tumors of unknown origin are decreasing the tumor load while controlling symptoms with chemotherapy and local modality treatments.
Appendix
Available only for authorised users
Literature
1.
go back to reference Crocetti E, Paci E: Malignant carcinoids in the USA, SEER 1992–1999: an epidemiological study with 6830 cases. Eur J Cancer Prev. 2003, 12: 191-194. 10.1097/00008469-200306000-00004.CrossRefPubMed Crocetti E, Paci E: Malignant carcinoids in the USA, SEER 1992–1999: an epidemiological study with 6830 cases. Eur J Cancer Prev. 2003, 12: 191-194. 10.1097/00008469-200306000-00004.CrossRefPubMed
2.
go back to reference Taal BG, Visser O: Epidemiology of neuroendocrine tumours. Neuroendocrinology. 2004, 80 (Suppl 1): 3-7.CrossRefPubMed Taal BG, Visser O: Epidemiology of neuroendocrine tumours. Neuroendocrinology. 2004, 80 (Suppl 1): 3-7.CrossRefPubMed
3.
go back to reference Robertson RG, Geieger WJ, Davis NB: Carcinoid tumors. Am Fam Physician. 2006, 74: 429-434.PubMed Robertson RG, Geieger WJ, Davis NB: Carcinoid tumors. Am Fam Physician. 2006, 74: 429-434.PubMed
4.
go back to reference Zuetenhorst JM, Taal BG: Metastatic carcinoid tumors: a clinical review. Oncologist. 2005, 10: 123-131. 10.1634/theoncologist.10-2-123.CrossRefPubMed Zuetenhorst JM, Taal BG: Metastatic carcinoid tumors: a clinical review. Oncologist. 2005, 10: 123-131. 10.1634/theoncologist.10-2-123.CrossRefPubMed
5.
go back to reference Meijer WG, van der Veer E, Jager PL, van der Jagt EJ, Piers BA, Kema IP, de Vries EG, Willemse PH: Bone metastases in carcinoid tumors: clinical features, imaging characteristics, and markers of bone metabolism. J Nucl Med. 2003, 44: 184-191.PubMed Meijer WG, van der Veer E, Jager PL, van der Jagt EJ, Piers BA, Kema IP, de Vries EG, Willemse PH: Bone metastases in carcinoid tumors: clinical features, imaging characteristics, and markers of bone metabolism. J Nucl Med. 2003, 44: 184-191.PubMed
6.
go back to reference Keiser J, Nakakura EK, Imhoff L, Mayorga MA, Bobiak S, Venook AP, Bergsland EK: Incidence and natural history of bone metastases in neuroendocrine tumors [Abstract]. J Clin Oncol. 2012, 30 (Suppl 4): 340- Keiser J, Nakakura EK, Imhoff L, Mayorga MA, Bobiak S, Venook AP, Bergsland EK: Incidence and natural history of bone metastases in neuroendocrine tumors [Abstract]. J Clin Oncol. 2012, 30 (Suppl 4): 340-
7.
go back to reference Hori T, Yasuda T, Suzuki K, Kanamori M, Kimura T: Skeletal metastasis of carcinoid tumors: two case reports and review of the literature. Oncol Lett. 2012, 3: 1105-1108.PubMedPubMedCentral Hori T, Yasuda T, Suzuki K, Kanamori M, Kimura T: Skeletal metastasis of carcinoid tumors: two case reports and review of the literature. Oncol Lett. 2012, 3: 1105-1108.PubMedPubMedCentral
8.
go back to reference Feldman JM, O’Dorisio TM: Role of neuropeptides and serotonin in the diagnosis of carcinoid tumors. Am J Med. 1986, 81: 41-48. 10.1016/0002-9343(86)90583-8.CrossRefPubMed Feldman JM, O’Dorisio TM: Role of neuropeptides and serotonin in the diagnosis of carcinoid tumors. Am J Med. 1986, 81: 41-48. 10.1016/0002-9343(86)90583-8.CrossRefPubMed
9.
go back to reference Eriksson B, Öberg K, Stridsberg M: Tumor markers in neuroendocrine tumors. Digestion. 2000, 62 (Suppl 1): 33-38.CrossRefPubMed Eriksson B, Öberg K, Stridsberg M: Tumor markers in neuroendocrine tumors. Digestion. 2000, 62 (Suppl 1): 33-38.CrossRefPubMed
10.
go back to reference Öberg K, Janson ET, Eriksson B: Tumour markers in neuroendocrine tumours. Ital J Gastroenterol Hepatol. 1999, 31 (Suppl 2): S160-S162.PubMed Öberg K, Janson ET, Eriksson B: Tumour markers in neuroendocrine tumours. Ital J Gastroenterol Hepatol. 1999, 31 (Suppl 2): S160-S162.PubMed
11.
go back to reference Nehar D, Lombard–Bohas C, Olivieri S, Claustrat B, Chayvialle JA, Penes MC, Sassolas G, Borson-Chazot F: Interest of chromogranin A for diagnosis and follow-up of endocrine tumours. Clin Endocrinol (Oxf). 2004, 60: 644-652. 10.1111/j.1365-2265.2004.02030.x.CrossRef Nehar D, Lombard–Bohas C, Olivieri S, Claustrat B, Chayvialle JA, Penes MC, Sassolas G, Borson-Chazot F: Interest of chromogranin A for diagnosis and follow-up of endocrine tumours. Clin Endocrinol (Oxf). 2004, 60: 644-652. 10.1111/j.1365-2265.2004.02030.x.CrossRef
12.
go back to reference Modlin IM, Lye KD, Kidd M: A 5-decade analysis of 13,715 carcinoid tumors. Cancer. 2003, 97: 934-959. 10.1002/cncr.11105.CrossRefPubMed Modlin IM, Lye KD, Kidd M: A 5-decade analysis of 13,715 carcinoid tumors. Cancer. 2003, 97: 934-959. 10.1002/cncr.11105.CrossRefPubMed
13.
go back to reference Yao JC, Hassan M, Phan A, Dagohoy C, Leary C, Mares JE, Abdalla EK, Fleming JB, Vauthey JN, Rashid A, Evans DB: One hundred years after “carcinoid”: epidemiology of and prognostic factors for neuroendocrine tumors in 35,825 cases in the United States. J Clin Oncol. 2008, 26: 3063-3072. 10.1200/JCO.2007.15.4377.CrossRefPubMed Yao JC, Hassan M, Phan A, Dagohoy C, Leary C, Mares JE, Abdalla EK, Fleming JB, Vauthey JN, Rashid A, Evans DB: One hundred years after “carcinoid”: epidemiology of and prognostic factors for neuroendocrine tumors in 35,825 cases in the United States. J Clin Oncol. 2008, 26: 3063-3072. 10.1200/JCO.2007.15.4377.CrossRefPubMed
14.
go back to reference Fjällskog ML, Granberg DP, Welin SL, Eriksson C, Oberg KE, Janson ET, Eriksson BK: Treatment with cisplatin and etoposide in patients with neuroendocrine tumors. Cancer. 2001, 92: 1101-1107. 10.1002/1097-0142(20010901)92:5<1101::AID-CNCR1426>3.0.CO;2-V.CrossRefPubMed Fjällskog ML, Granberg DP, Welin SL, Eriksson C, Oberg KE, Janson ET, Eriksson BK: Treatment with cisplatin and etoposide in patients with neuroendocrine tumors. Cancer. 2001, 92: 1101-1107. 10.1002/1097-0142(20010901)92:5<1101::AID-CNCR1426>3.0.CO;2-V.CrossRefPubMed
15.
go back to reference Mitry E, Baudin E, Ducreux M, Sabourin JC, Rufié P, Aparicio T, Lasser P, Elias D, Duvillard P, Schlumberger M, Rougier P: Treatment of poorly differentiated neuroendocrine tumours with etoposide and cisplatin. Br J Cancer. 1999, 81: 1351-1355. 10.1038/sj.bjc.6690325.CrossRefPubMedPubMedCentral Mitry E, Baudin E, Ducreux M, Sabourin JC, Rufié P, Aparicio T, Lasser P, Elias D, Duvillard P, Schlumberger M, Rougier P: Treatment of poorly differentiated neuroendocrine tumours with etoposide and cisplatin. Br J Cancer. 1999, 81: 1351-1355. 10.1038/sj.bjc.6690325.CrossRefPubMedPubMedCentral
Metadata
Title
Atypical presentation of carcinoid tumor with unresolved right shoulder pain: a case report
Authors
Nay Thi Tun
Rajen Oza
Publication date
01-12-2014
Publisher
BioMed Central
Published in
Journal of Medical Case Reports / Issue 1/2014
Electronic ISSN: 1752-1947
DOI
https://doi.org/10.1186/1752-1947-8-142

Other articles of this Issue 1/2014

Journal of Medical Case Reports 1/2014 Go to the issue